Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

THERANEXUS announces the formation of its scientific Board

04/06/2019
Download PDF File (375 Ko)

THERANEXUS to present new data on neuron-glia interactions at two scientific events

23/05/2019
Download PDF File (380 Ko)

THERANEXUS announces issuance of Chinese patent covering its drug candidate THN102

24/04/2019
Download PDF File (381 Ko)

THERANEXUS provides 2018 full-year results and update on activities

17/04/2019
Download PDF File (416 Ko)

THERANEXUS announces research collaboration with IRISA using artificial intelligence technologies to enhance therapeutic targeting of neuroglial interactions

09/04/2019
Download PDF File (376 Ko)

THERANEXUS to present new scientific data on drug candidate THN201 at AD/PD 2019, the 14th conference on Alzheimer's and Parkinson's diseases

26/03/2019
Download PDF File (377 Ko)

THERANEXUS announces preliminary results of phase II trial of THN102 on narcolepsy patients

27/02/2019
Download PDF File (296 Ko)

THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

13/02/2019
Download PDF File (395 Ko)

THERANEXUS set to receive €6.2 million in funding from the French Investments for the
Future program, managed by Bpifrance, for the development of Neurolead,
its new lead generation platform targeting neuro-glia interactions

29/01/2019
Download PDF File

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
13/12/2018
Download PDF File (370 Ko)